Your browser is no longer supported. Please, upgrade your browser.
Corbus Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)-1.78 Insider Own0.50% Shs Outstand81.88M Perf Week-7.91%
Market Cap207.46M Forward P/E- EPS next Y-0.73 Insider Trans-28.08% Shs Float77.54M Perf Month27.32%
Income-129.20M PEG- EPS next Q-0.25 Inst Own49.80% Short Float28.56% Perf Quarter90.98%
Sales5.90M P/S35.16 EPS this Y-14.50% Inst Trans-27.99% Short Ratio1.45 Perf Half Y-74.45%
Book/sh0.36 P/B6.47 EPS next Y54.70% ROA-167.70% Target Price1.88 Perf Year-52.35%
Cash/sh0.92 P/C2.53 EPS next 5Y- ROE-485.50% 52W Range0.91 - 9.78 Perf YTD86.40%
Dividend- P/FCF- EPS past 5Y-61.90% ROI- 52W High-76.18% Beta2.02
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low156.04% ATR0.39
Employees141 Current Ratio2.10 Sales Q/Q-53.80% Oper. Margin- RSI (14)46.72 Volatility11.70% 17.35%
OptionableYes Debt/Eq0.61 EPS Q/Q-32.50% Profit Margin- Rel Volume0.72 Prev Close2.40
ShortableYes LT Debt/Eq0.61 Earnings- Payout- Avg Volume15.24M Price2.33
Recom2.80 SMA20-15.06% SMA5013.72% SMA200-41.68% Volume11,019,778 Change-2.92%
Sep-08-20Downgrade ROTH Capital Buy → Neutral $40 → $3
Sep-08-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-08-20Downgrade Jefferies Buy → Hold $18 → $2.50
Sep-08-20Downgrade BTIG Research Buy → Neutral
Jul-07-20Initiated ROTH Capital Buy $40
Jun-17-20Initiated BTIG Research Buy $22
Mar-26-20Initiated Nomura Buy $12
Apr-05-19Initiated Jefferies Buy
Mar-20-19Initiated Oppenheimer Outperform $28
Jan-11-19Reiterated Cantor Fitzgerald Overweight $36 → $38
Dec-26-18Initiated H.C. Wainwright Buy $24
Dec-07-18Initiated RBC Capital Mkts Outperform $23
Oct-24-18Initiated B. Riley FBR Buy $22
Jan-19-18Initiated Raymond James Outperform $24
Dec-14-17Reiterated Cantor Fitzgerald Overweight $24 → $28
Nov-08-17Reiterated Noble Financial Buy $16 → $20
Sep-29-17Resumed Noble Financial Buy $16
Mar-30-17Reiterated Cantor Fitzgerald Overweight $17 → $24
Nov-15-16Reiterated JMP Securities Mkt Outperform $9 → $20
Nov-11-16Reiterated Noble Financial Buy $19
Feb-11-21 11:29AM  
Feb-02-21 10:44AM  
Jan-20-21 08:05AM  
Jan-14-21 08:30AM  
Jan-12-21 08:49AM  
Jan-09-21 02:16AM  
Dec-07-20 10:43PM  
Dec-04-20 08:44AM  
Dec-01-20 10:28AM  
Nov-16-20 09:54AM  
Nov-12-20 08:05AM  
Nov-11-20 10:00AM  
Nov-10-20 03:31PM  
Nov-09-20 10:27AM  
Nov-03-20 08:05AM  
Oct-29-20 12:35PM  
Oct-23-20 08:05AM  
Oct-21-20 08:05AM  
Oct-08-20 08:05AM  
Oct-07-20 10:46AM  
Oct-06-20 07:05AM  
Oct-04-20 09:46AM  
Sep-25-20 08:53AM  
Sep-24-20 09:54AM  
Sep-10-20 10:01AM  
Sep-08-20 10:00AM  
Sep-04-20 09:40AM  
Aug-25-20 09:19AM  
Aug-24-20 06:30AM  
Aug-20-20 10:17AM  
Aug-16-20 08:15AM  
Aug-14-20 10:31AM  
Aug-06-20 07:05AM  
Aug-05-20 09:25AM  
Aug-03-20 08:05AM  
Jul-30-20 08:05AM  
Jul-29-20 08:05AM  
Jul-21-20 10:02AM  
Jul-17-20 04:21PM  
Jul-15-20 02:38PM  
Jul-08-20 08:05AM  
Jul-05-20 09:58PM  
Jun-29-20 08:05AM  
Jun-22-20 08:05AM  
Jun-18-20 10:56AM  
Jun-01-20 09:00AM  
May-28-20 06:53AM  
May-27-20 08:05AM  
May-22-20 08:05AM  
May-18-20 03:09AM  
May-15-20 12:00PM  
May-14-20 09:30AM  
May-11-20 09:55AM  
May-04-20 08:05AM  
Apr-30-20 04:15PM  
Apr-29-20 08:05AM  
Apr-28-20 07:05AM  
Apr-02-20 08:58AM  
Mar-14-20 08:52AM  
Mar-12-20 08:55AM  
Mar-10-20 08:05AM  
Mar-05-20 08:05AM  
Mar-03-20 12:30PM  
Feb-11-20 04:01PM  
Feb-10-20 08:58AM  
Feb-07-20 09:02AM  
Feb-06-20 04:01PM  
Jan-31-20 03:45PM  
Jan-25-20 08:09AM  
Dec-19-19 08:07AM  
Dec-17-19 04:07PM  
Dec-09-19 08:05AM  
Nov-18-19 08:17AM  
Nov-16-19 09:40PM  
Nov-12-19 08:05AM  
Nov-11-19 08:05AM  
Nov-07-19 11:15AM  
Nov-05-19 01:00PM  
Nov-04-19 08:05AM  
Nov-01-19 12:08PM  
Oct-13-19 10:06AM  
Oct-03-19 08:05AM  
Oct-01-19 09:03AM  
Sep-13-19 07:21AM  
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moran Sean F.Chief Financial OfficerDec 21Option Exercise1.4087,500122,500437,110Dec 22 04:42 PM
Moran Sean F.Chief Financial OfficerDec 21Sale1.7587,500153,125349,610Dec 22 04:42 PM
Moran Sean F.Chief Financial OfficerDec 18Option Exercise1.0053,61053,610403,220Dec 22 04:42 PM
Moran Sean F.Chief Financial OfficerDec 18Sale1.4053,61075,054349,610Dec 22 04:42 PM
Moran Sean F.Chief Financial OfficerDec 16Option Exercise0.1736,9236,118386,533Dec 18 04:44 PM
Moran Sean F.Chief Financial OfficerDec 16Sale1.3236,92348,628349,610Dec 18 04:44 PM
Cohen YuvalChief Executive OfficerNov 11Buy1.214,2405,12675,330Nov 12 10:28 AM
Millian Craig StuartChief Commercial OfficerMar 17Buy4.252,0008,50012,000Mar 18 01:18 PM
Cohen YuvalChief Executive OfficerMar 17Buy3.494,30015,00771,090Mar 17 01:14 PM
Discordia Robert PaulChief Operating OfficerMar 17Buy3.542,84010,05435,490Mar 18 11:21 AM
White BarbaraChief Medical OfficerMar 17Buy3.6315,60656,650206,217Mar 18 10:37 AM